IVIg Immune Reconstitution Treatment Alleviates the State of Persistent Immune Activation and Suppressed CD4 T Cell Counts in CVID

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Paquin Proulx, Dominic ^a   Santos, Bianca A N ^b   Carvalho, Karina I ^b   Toledo Barros, Myrthes ^b   Barreto de Oliveira, Ana Karolina ^b   Kokron, Cristina M ^b   Kalil, Jorge ^b   Moll, Markus ^a   Kallas, Esper G ^b   Sandberg, Johan K ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD83 ANTIGEN; IMMUNOGLOBULIN; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE ACTIVATION; IMMUNE RESPONSE; MALE; MONOCYTE; MYELOID DENDRITIC CELL; NATURAL KILLER T CELL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, CD80; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; YOUNG ADULT;

EID: 84885161896     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075199     Document Type: Article

References (46)

1. Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS, (2008) Common variable immunodeficiency: a new look at an old disease. Lancet 372: 489-502.
2. Salzer U, Unger S, Warnatz K, (2012) Common variable immunodeficiency (CVID): exploring the multiple dimensions of a heterogeneous disease. Ann N Y Acad Sci 1250: 41-49.
3. Cunningham-Rundles C, (2010) How I treat common variable immune deficiency. Blood 116: 7-15.
4. Gouilleux-Gruart V, Chapel H, Chevret S, Lucas M, Malphettes M, et al. (2013) Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Clin Exp Immunol 171: 186-194.
5. Gelfand EW, (2012) Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 367: 2015-2025.
6. Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J, (2011) Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol 164 Suppl 2: 2-5.
7. Barbosa RR, Silva SP, Silva SL, Tendeiro R, Melo AC, et al. (2012) Monocyte activation is a feature of common variable immunodeficiency irrespective of plasma lipopolysaccharide levels. Clin Exp Immunol 169: 263-272.
8. Litzman J, Nechvatalova J, Xu J, Ticha O, Vlkova M, et al. (2012) Chronic immune activation in common variable immunodeficiency (CVID) is associated with elevated serum levels of soluble CD14 and CD25 but not endotoxaemia. Clin Exp Immunol 170: 321-332.
9. Giorgi JV, Detels R, (1989) T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin Immunol Immunopathol 52: 10-18.
10. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, et al. (1999) Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 179: 859-870.
11. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, et al. (2003) Persistent immune activation in HIV-1 infection is associated with progression to AIDS. Aids 17: 1881-1888.
12. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, et al. (2004) Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104: 942-947.
13. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, et al. (2008) Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 197: 126-133.
14. Eller MA, Blom KG, Gonzalez VD, Eller LA, Naluyima P, et al. (2011) Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans. PLoS ONE 6: e18779.
15. Kaufmann DE, Walker BD, (2009) PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 182: 5891-5897.
16. Khaitan A, Unutmaz D, (2011) Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep 8: 4-11.
17. Ballow M, Allen C, (2011) Intravenous immunoglobulin modulates the maturation of TLR 4-primed peripheral blood monocytes. Clin Immunol 139: 208-214.
18. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, et al. (2003) Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101: 758-765.
19. Sandler NG, Douek DC, (2012) Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 10: 655-666.
20. Klatt NR, Funderburg NT, Brenchley JM, (2012) Microbial translocation, immune activation, and HIV disease. Trends Microbiol.
21. Leeansyah E, Malone DF, Anthony DD, Sandberg JK, (2013) Soluble biomarkers of HIV transmission, disease progression and comorbidities. Curr Opin HIV AIDS 8: 117-124.
22. Brenchley JM, Douek DC, (2012) Microbial translocation across the GI tract. Annu Rev Immunol 30: 149-173.
23. Sandberg JK, Ljunggren HG, (2005) Development and function of CD1d-restricted NKT cells: influence of sphingolipids, SAP and sex. Trends Immunol 26: 347-349.
24. Van Kaer L, Parekh VV, Wu L, (2012) Invariant natural killer T cells as sensors and managers of inflammation. Trends Immunol.
25. Carvalho KI, Melo KM, Bruno FR, Snyder-Cappione JE, Nixon DF, et al. (2010) Skewed distribution of circulating activated natural killer T (NKT) cells in patients with common variable immunodeficiency disorders (CVID). PLoS ONE 5.
26. Josefowicz SZ, Lu LF, Rudensky AY, (2012) Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 30: 531-564.
27. Melo KM, Carvalho KI, Bruno FR, Ndhlovu LC, Ballan WM, et al. (2009) A decreased frequency of regulatory T cells in patients with common variable immunodeficiency. PLoS ONE 4: e6269.
28. Genre J, Errante PR, Kokron CM, Toledo-Barros M, Camara NO, et al. (2009) Reduced frequency of CD4(+)CD25(HIGH)FOXP3(+) cells and diminished FOXP3 expression in patients with Common Variable Immunodeficiency: a link to autoimmunity? Clin Immunol 132: 215-221.
29. Kasztalska K, Ciebiada M, Cebula-Obrzut B, Gorski P, (2011) Intravenous immunoglobulin replacement therapy in the treatment of patients with common variable immunodeficiency disease: an open-label prospective study. Clin Drug Investig 31: 299-307.
30. Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, et al. (2007) Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 8: 1246-1254.
31. Grassi F, Hosmalin A, McIlroy D, Calvez V, Debre P, et al. (1999) Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. AIDS 13: 759-766.
32. Donaghy H, Pozniak A, Gazzard B, Qazi N, Gilmour J, et al. (2001) Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 98: 2574-2576.
33. Barron MA, Blyveis N, Palmer BE, MaWhinney S, Wilson CC, (2003) Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals. J Infect Dis 187: 26-37.
34. Eggena MP, Barugahare B, Jones N, Okello M, Mutalya S, et al. (2005) Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol 174: 4407-4414.
35. Ndhlovu LC, Loo CP, Spotts G, Nixon DF, Hecht FM, (2008) FOXP3 expressing CD127lo CD4+ T cells inversely correlate with CD38+ CD8+ T cell activation levels in primary HIV-1 infection. J Leukoc Biol 83: 254-262.
36. Sandberg JK, Fast NM, Palacios EH, Fennelly G, Dobroszycki J, et al. (2002) Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol 76: 7528-7534.
37. Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, et al. (2002) CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med 195: 869-879.
38. van der Vliet HJ, von Blomberg BM, Hazenberg MD, Nishi N, Otto SA, et al. (2002) Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol 168: 1490-1495.
39. Moll M, Kuylenstierna C, Gonzalez VD, Andersson SK, Bosnjak L, et al. (2009) Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur J Immunol 39: 902-911.
40. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371.
41. Giovannetti A, Pierdominici M, Mazzetta F, Marziali M, Renzi C, et al. (2007) Unravelling the complexity of T cell abnormalities in common variable immunodeficiency. J Immunol 178: 3932-3943.
42. Nordoy I, Muller F, Aukrust P, Froland SS, (1998) Adhesion molecules in common variable immunodeficiency (CVID)-a decrease in L-selectin-positive T lymphocytes. Clin Exp Immunol 114: 258-263.
43. Aukrust P, Hestdal K, Lien E, Bjerkeli V, Nordoy I, et al. (1997) Effects of intravenous immunoglobulin in vivo on abnormally increased tumor necrosis factor-alpha activity in human immunodeficiency virus type 1 infection. J Infect Dis 176: 913-923.
44. Vermeulen JN, Prins JM, Bunnik E, Hack CE, Jurriaans S, et al. (2007) Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals. AIDS Res Hum Retroviruses 23: 1348-1353.
45. Shulzhenko N, Morgun A, Hsiao W, Battle M, Yao M, et al. (2011) Crosstalk between B lymphocytes, microbiota and the intestinal epithelium governs immunity versus metabolism in the gut. Nat Med 17: 1585-1593.
46. Young GR, Eksmond U, Salcedo R, Alexopoulou L, Stoye JP, et al. (2012) Resurrection of endogenous retroviruses in antibody-deficient mice. Nature 491: 774-778.